Who holds JNJ (JOHNSON & JOHNSON)?

JNJ

JOHNSON & JOHNSON

Data as of 2026 Q1 (03-31) · 13F snapshot

Summary

JOHNSON & JOHNSON (JNJ) is held by 13 tracked hedge-fund managers, a combined reported value of ~$3.17B; the largest are Ken Griffin, Ken Griffin, Ken Griffin. This quarter: 1 new, 1 added, 3 trimmed, 1 closed. 20 members of Congress have disclosed STOCK Act trades. Data as of 2026 Q1, from public SEC 13F filings, delayed up to ~45 days.

Attention · HighThis quarter · Cooling

Gurus holding13

Congress trades20

Price$263.40vs quarter-end+7.76%

Sectors1

This quarter's moves

New1

Added1

Trimmed / sold4

Top holderKen Griffin

Ken GriffinCALL—

Value $913.77M— of portfolio3,738,2002026 Q1

Ken GriffinPUT—

Value $615.45M— of portfolio2,517,8002026 Q1

Ken GriffinAdd

Value $472.01M0.3% of portfolio1,930,9762026 Q1

Izzy EnglanderPUT—

Value $298.53M— of portfolio1,221,3002026 Q1

Ray DalioTrim

Value $170.35M0.8% of portfolio696,8842026 Q1

Izzy EnglanderCALL—

Value $137.67M— of portfolio563,2002026 Q1

Steven CohenCALL—

Value $81.91M— of portfolio335,1002026 Q1

Steven CohenPUT—

Value $58.37M— of portfolio238,8002026 Q1

Warren BuffettHold

Value $54.14M0.0% of portfolio327,1002023 Q2

Chase ColemanTrim

Value $33.30M1.3% of portfolio633,0002009 Q1

Dan LoebNew

Value $32.85M0.7% of portfolio500,0002007 Q3

Investor	Period	Value	Shares	% of portfolio	Action
Ken GriffinCALL	2026 Q1	$913.77M	3,738,200	—	—
Ken GriffinPUT	2026 Q1	$615.45M	2,517,800	—	—
Ken Griffin	2026 Q1	$472.01M	1,930,976	0.3%	Add
Izzy EnglanderPUT	2026 Q1	$298.53M	1,221,300	—	—
Ray Dalio	2026 Q1	$170.35M	696,884	0.8%	Trim
Izzy EnglanderCALL	2026 Q1	$137.67M	563,200	—	—
Steven CohenCALL	2026 Q1	$81.91M	335,100	—	—
Steven CohenPUT	2026 Q1	$58.37M	238,800	—	—
Warren Buffett	2023 Q2	$54.14M	327,100	0.0%	Hold
Chase Coleman	2009 Q1	$33.30M	633,000	1.3%	Trim
Dan Loeb	2007 Q3	$32.85M	500,000	0.7%	New

Insider Trading

Officers · directors · Form 4

Vanessa Broadhurst
EVP, Global Corp Affairs
Buy$1.44M
11,129 @ $129.51Traded 2026-07-20Filed 2026-07-21
Vanessa Broadhurst
EVP, Global Corp Affairs
Sell$5.79M
23,054 @ $251.27Traded 2026-07-20Filed 2026-07-21
Vanessa Broadhurst
EVP, Global Corp Affairs
Buy$1.57M
11,925 @ $131.94Traded 2026-07-20Filed 2026-07-21
Kathryn E Wengel
EVP, Chief TO and Risk Officer
Sell$2.41M
10,000 @ $241.15Traded 2026-06-11Filed 2026-06-12
Kathryn E Wengel
EVP, Chief TO and Risk Officer
Buy$1.16M
10,000 @ $115.67Traded 2026-06-11Filed 2026-06-12
Eugene A. Woods
Director
Buy$37.5K
161Traded 2026-06-09Filed 2026-06-11
Daniel E Pinto
Director
Buy$31.3K
134Traded 2026-06-09Filed 2026-06-11
Marillyn A Hewson
Director
Buy$50.0K
215Traded 2026-06-09Filed 2026-06-11
REED JOHN C
EVP, Innovative Medicine, R&D
Sell$2.53M
11,002 @ $229.85Traded 2026-05-01Filed 2026-05-04
REED JOHN C
EVP, Innovative Medicine, R&D
Buy
25,255 @ $0.00Traded 2026-05-01Filed 2026-05-04
Hubert Joly
Director
Buy
975Traded 2026-04-23Filed 2026-04-27
Mark B. Mcclellan
Director
Buy
975Traded 2026-04-23Filed 2026-04-27
John G Morikis
Director
Buy
1,540Traded 2026-04-23Filed 2026-04-27
Paula A Johnson
Director
Buy
975Traded 2026-04-23Filed 2026-04-27
Daniel E Pinto
Director
Buy
1,712Traded 2026-04-23Filed 2026-04-27
Mark A Weinberger
Director
Buy
975Traded 2026-04-23Filed 2026-04-27
Eugene A. Woods
Director
Buy
975Traded 2026-04-23Filed 2026-04-27
Mary C Beckerle
Director
Buy
975Traded 2026-04-23Filed 2026-04-27
Marillyn A Hewson
Director
Buy
975Traded 2026-04-23Filed 2026-04-27
Jennifer A Doudna
Director
Buy
975Traded 2026-04-23Filed 2026-04-27
Nadja West
Director
Buy
975Traded 2026-04-23Filed 2026-04-27
Eugene A. Woods
Director
Buy$37.5K
155Traded 2026-03-10Filed 2026-03-12
Daniel E Pinto
Director
Buy$31.3K
129Traded 2026-03-10Filed 2026-03-12
Robert J Decker
VP Corporate Controller
Buy$471.4K
4,075 @ $115.67Traded 2026-02-27Filed 2026-03-03

Insider transactions are public SEC Form 4 disclosures (company officers, directors, 10% owners), for research only — not investment advice.

Data from public SEC 13F & STOCK Act filings, delayed up to ~45 days, partial holdings only — for research, not investment advice.